A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients-Reference-Cited by-同舟云学术

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients

Published:2022-04-17 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Le Naour Julie¹²³^ORCID,Sztupinszki Zsofia⁴⁵⁶^ORCID,Carbonnier Vincent¹²³,Casiraghi Odile⁷,Marty Virginie⁸,Galluzzi Lorenzo⁹¹⁰¹¹,Szallasi Zoltan⁴⁵⁶,Kroemer Guido¹²¹²¹³^ORCID,Vacchelli Erika¹²^ORCID

Affiliation:

1. Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Institut Universitaire de France, Paris, France

2. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France

3. Université Paris Sud, Paris Saclay, Faculty of Medicine Kremlin Bicêtre, France

4. Computational Health Informatics Program (CHIP), Boston Children’s Hospital, Boston, MA, USA

5. Harvard Medical School, Boston, MA, USA

6. Danish Cancer Society Research Center, Copenhagen, Denmark

7. Department of Head and Neck Surgical and Medical Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France

8. Experimental and Translational Pathology Platform (PETRA), AMMICa Inserm US23/UMS CNRS3655, Gustave Roussy Cancer Campus, Villejuif, France

9. Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA

10. Sandra and Edward Meyer Cancer Center, New York, NY, USA

11. Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA

12. Institut du Cancer Paris CARPEMAP-HP, Hôpital Européen Georges Pompidou, Pôle de Biologie, Paris, France

13. Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France

Funder

The author(s) reported there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2059878

Reference155 articles.

1. The molecular landscape of head and neck cancer

2. Head and neck cancer

3. The localization and risk factors of squamous cell carcinoma in the oral cavity: A retrospective study of 1501 cases

4. Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and clinical significance of immunogenic cell death biomarkers in chemoresistance and immunoregulation of head and neck squamous cell carcinoma;Biomedicine & Pharmacotherapy;2023-11

2. ATHENA: an independently validated autophagy-related epigenetic prognostic prediction model of head and neck squamous cell carcinoma;Clinical Epigenetics;2023-06-09

3. Immunogenic cell death in cancer: concept and therapeutic implications;Journal of Translational Medicine;2023-03-02